Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: Results from the Korean Multicentre Endeavor (KOMER) acute myocardial infarction (AMI) trial

Woong Chol Kang, Taehoon Ahn, Kyounghoon Lee, Seung Hwan Han, Eak Kyun Shin, Myung Ho Jeong, Jung Han Yoon, Jong Seon Park, Jang Ho Bae, Seung Ho Hur, Seung Woon Rha, Seok Kyu Oh, Doo Il Kim, Yangsoo Jang, Jae Woong Choi, Byung Ok Kim

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Aims: The aim of this study was to compare the efficacy and safety of zotarolimus-eluting stents (ZES), sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).Methods and results: This study was a prospective, single-blind, multicentre, randomised trial. The primary endpoint was major adverse cardiac events (MACE) at 12 months post-procedure, defined as cardiac death, recurrent myocardial infarction (MI), or ischaemia-driven target lesion revascularisation (TLR). An angiographic substudy was performed at nine months among 348 patients. From October 2006 to April 2008, 611 patients with STEMI undergoing primary PCI were randomly assigned to treatment with ZES (n=205), SES (n=204), or PES (n=202). The cumulative incidence of MACE was 5.9% in the ZES group, 3.4% in the SES group and 5.7% in the PES group at 12-month follow-up (p=0.457). There was a trend towards a lower rate of ischaemia-driven TLR at 12- (p=0.092) and 18-month (p=0.080) follow-up in the SES group compared to the ZES and PES groups. No difference was observed in rates of cardiac death, recurrent MI and combined death and/or recurrent MI among three groups at 12- and 18-month follow-up. The rate of stent thrombosis was similar among the three groups (2.0% in each group, p=1.000).Conclusions: As compared with SES and PES, the use of ZES in patients with STEMI undergoing primary PCI, showed similar rates of MACE, cardiac death and recurrent MI at 12 and 18 months. There was a trend towards a higher rate of TLR with ZES or PES compared to SES.

Original languageEnglish
Pages (from-to)936-943
Number of pages8
JournalEuroIntervention
Volume7
Issue number8
DOIs
Publication statusPublished - 2011 Dec 1

Fingerprint

Sirolimus
Percutaneous Coronary Intervention
Paclitaxel
Stents
Myocardial Infarction
ST Elevation Myocardial Infarction
zotarolimus

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Kang, Woong Chol ; Ahn, Taehoon ; Lee, Kyounghoon ; Han, Seung Hwan ; Shin, Eak Kyun ; Jeong, Myung Ho ; Yoon, Jung Han ; Park, Jong Seon ; Bae, Jang Ho ; Hur, Seung Ho ; Rha, Seung Woon ; Oh, Seok Kyu ; Kim, Doo Il ; Jang, Yangsoo ; Choi, Jae Woong ; Kim, Byung Ok. / Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction : Results from the Korean Multicentre Endeavor (KOMER) acute myocardial infarction (AMI) trial. In: EuroIntervention. 2011 ; Vol. 7, No. 8. pp. 936-943.
@article{fe84f0e70d0146909cddc017e6fc4464,
title = "Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: Results from the Korean Multicentre Endeavor (KOMER) acute myocardial infarction (AMI) trial",
abstract = "Aims: The aim of this study was to compare the efficacy and safety of zotarolimus-eluting stents (ZES), sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).Methods and results: This study was a prospective, single-blind, multicentre, randomised trial. The primary endpoint was major adverse cardiac events (MACE) at 12 months post-procedure, defined as cardiac death, recurrent myocardial infarction (MI), or ischaemia-driven target lesion revascularisation (TLR). An angiographic substudy was performed at nine months among 348 patients. From October 2006 to April 2008, 611 patients with STEMI undergoing primary PCI were randomly assigned to treatment with ZES (n=205), SES (n=204), or PES (n=202). The cumulative incidence of MACE was 5.9{\%} in the ZES group, 3.4{\%} in the SES group and 5.7{\%} in the PES group at 12-month follow-up (p=0.457). There was a trend towards a lower rate of ischaemia-driven TLR at 12- (p=0.092) and 18-month (p=0.080) follow-up in the SES group compared to the ZES and PES groups. No difference was observed in rates of cardiac death, recurrent MI and combined death and/or recurrent MI among three groups at 12- and 18-month follow-up. The rate of stent thrombosis was similar among the three groups (2.0{\%} in each group, p=1.000).Conclusions: As compared with SES and PES, the use of ZES in patients with STEMI undergoing primary PCI, showed similar rates of MACE, cardiac death and recurrent MI at 12 and 18 months. There was a trend towards a higher rate of TLR with ZES or PES compared to SES.",
author = "Kang, {Woong Chol} and Taehoon Ahn and Kyounghoon Lee and Han, {Seung Hwan} and Shin, {Eak Kyun} and Jeong, {Myung Ho} and Yoon, {Jung Han} and Park, {Jong Seon} and Bae, {Jang Ho} and Hur, {Seung Ho} and Rha, {Seung Woon} and Oh, {Seok Kyu} and Kim, {Doo Il} and Yangsoo Jang and Choi, {Jae Woong} and Kim, {Byung Ok}",
year = "2011",
month = "12",
day = "1",
doi = "10.4244/EIJV7I8A148",
language = "English",
volume = "7",
pages = "936--943",
journal = "EuroIntervention",
issn = "1774-024X",
publisher = "EuroPCR",
number = "8",

}

Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction : Results from the Korean Multicentre Endeavor (KOMER) acute myocardial infarction (AMI) trial. / Kang, Woong Chol; Ahn, Taehoon; Lee, Kyounghoon; Han, Seung Hwan; Shin, Eak Kyun; Jeong, Myung Ho; Yoon, Jung Han; Park, Jong Seon; Bae, Jang Ho; Hur, Seung Ho; Rha, Seung Woon; Oh, Seok Kyu; Kim, Doo Il; Jang, Yangsoo; Choi, Jae Woong; Kim, Byung Ok.

In: EuroIntervention, Vol. 7, No. 8, 01.12.2011, p. 936-943.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction

T2 - Results from the Korean Multicentre Endeavor (KOMER) acute myocardial infarction (AMI) trial

AU - Kang, Woong Chol

AU - Ahn, Taehoon

AU - Lee, Kyounghoon

AU - Han, Seung Hwan

AU - Shin, Eak Kyun

AU - Jeong, Myung Ho

AU - Yoon, Jung Han

AU - Park, Jong Seon

AU - Bae, Jang Ho

AU - Hur, Seung Ho

AU - Rha, Seung Woon

AU - Oh, Seok Kyu

AU - Kim, Doo Il

AU - Jang, Yangsoo

AU - Choi, Jae Woong

AU - Kim, Byung Ok

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Aims: The aim of this study was to compare the efficacy and safety of zotarolimus-eluting stents (ZES), sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).Methods and results: This study was a prospective, single-blind, multicentre, randomised trial. The primary endpoint was major adverse cardiac events (MACE) at 12 months post-procedure, defined as cardiac death, recurrent myocardial infarction (MI), or ischaemia-driven target lesion revascularisation (TLR). An angiographic substudy was performed at nine months among 348 patients. From October 2006 to April 2008, 611 patients with STEMI undergoing primary PCI were randomly assigned to treatment with ZES (n=205), SES (n=204), or PES (n=202). The cumulative incidence of MACE was 5.9% in the ZES group, 3.4% in the SES group and 5.7% in the PES group at 12-month follow-up (p=0.457). There was a trend towards a lower rate of ischaemia-driven TLR at 12- (p=0.092) and 18-month (p=0.080) follow-up in the SES group compared to the ZES and PES groups. No difference was observed in rates of cardiac death, recurrent MI and combined death and/or recurrent MI among three groups at 12- and 18-month follow-up. The rate of stent thrombosis was similar among the three groups (2.0% in each group, p=1.000).Conclusions: As compared with SES and PES, the use of ZES in patients with STEMI undergoing primary PCI, showed similar rates of MACE, cardiac death and recurrent MI at 12 and 18 months. There was a trend towards a higher rate of TLR with ZES or PES compared to SES.

AB - Aims: The aim of this study was to compare the efficacy and safety of zotarolimus-eluting stents (ZES), sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).Methods and results: This study was a prospective, single-blind, multicentre, randomised trial. The primary endpoint was major adverse cardiac events (MACE) at 12 months post-procedure, defined as cardiac death, recurrent myocardial infarction (MI), or ischaemia-driven target lesion revascularisation (TLR). An angiographic substudy was performed at nine months among 348 patients. From October 2006 to April 2008, 611 patients with STEMI undergoing primary PCI were randomly assigned to treatment with ZES (n=205), SES (n=204), or PES (n=202). The cumulative incidence of MACE was 5.9% in the ZES group, 3.4% in the SES group and 5.7% in the PES group at 12-month follow-up (p=0.457). There was a trend towards a lower rate of ischaemia-driven TLR at 12- (p=0.092) and 18-month (p=0.080) follow-up in the SES group compared to the ZES and PES groups. No difference was observed in rates of cardiac death, recurrent MI and combined death and/or recurrent MI among three groups at 12- and 18-month follow-up. The rate of stent thrombosis was similar among the three groups (2.0% in each group, p=1.000).Conclusions: As compared with SES and PES, the use of ZES in patients with STEMI undergoing primary PCI, showed similar rates of MACE, cardiac death and recurrent MI at 12 and 18 months. There was a trend towards a higher rate of TLR with ZES or PES compared to SES.

UR - http://www.scopus.com/inward/record.url?scp=84855395899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855395899&partnerID=8YFLogxK

U2 - 10.4244/EIJV7I8A148

DO - 10.4244/EIJV7I8A148

M3 - Article

C2 - 21959255

AN - SCOPUS:84855395899

VL - 7

SP - 936

EP - 943

JO - EuroIntervention

JF - EuroIntervention

SN - 1774-024X

IS - 8

ER -